dc.contributor.author
Vázquez Carrera, Manuel
dc.date.issued
2020-05-25T11:07:48Z
dc.date.issued
2020-05-25T11:07:48Z
dc.date.issued
2016-03-20
dc.date.issued
2020-05-25T11:07:49Z
dc.identifier
https://hdl.handle.net/2445/162264
dc.description.abstract
Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Elsevier Current Trends
dc.relation
Versió postprint del document publicat a: https://doi.org/10.1016/j.tem.2016.02.008
dc.relation
Trends in Endocrinology and Metabolism, 2016, vol. 27, num. 5, p. 319-334
dc.relation
https://doi.org/10.1016/j.tem.2016.02.008
dc.rights
cc-by-nc-nd (c) Elsevier Current Trends, 2016
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Resistència a la insulina
dc.subject
Insulin resistance
dc.title
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion
